Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 18 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Bizumentary to Premiere Sept. 24 Across National Networks
Beeline Holdings (NASDAQ: BLNE) announced that its “Bizumentary,” produced in partnership with Emmy Award-winning Loft…
-
QualityStocksNewsBreaks – Nocera, Inc. (NASDAQ: NCRA) Enters Worldwide Joint Distribution Agreement With E-PRO
Nocera (NASDAQ: NCRA) entered into a Strategic Partnership and Joint Distribution Agreement with Taiwan-based E-PRO…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Appoints Brian Goldenberg as Chief Financial Officer
Versus Systems (NASDAQ: VS) announced the appointment of Brian Goldenberg, CPA, as Chief Financial Officer,…